Skip to main content
logo
SpringWorks Therapeutics, Inc. (SWTX)
Jul 1, 2025 - SWTX was delisted (reason: acquired by Merck KGaA)
46.99
0.00 (0.00%)
Inactive · Last trade price on Jun 30, 2025

SpringWorks Therapeutics Financials Overview

Millions USD. Fiscal year is Jan - Dec.

Revenue & Profits
Chart
Fiscal YearTTMFY 2024FY 2023FY 2022FY 2021FY 2020
Period EndingMar '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
Revenue
219.67191.595.45--35
Revenue Growth
730.42%3417.33%----
Gross Profit
204.8179.045.03--35
Operating Income
-264.74-278.13-343.01-280.67-173.47-46.32
Net Income
-253.93-258.13-325.1-277.42-173.91-45.57
Earnings Per Share
-3.41-3.48-5.15-5.21-3.59-1.05
EPS Growth
------

Cash & Debt
Chart
Fiscal YearCurrentFY 2024FY 2023FY 2022FY 2021FY 2020
Period EndingMar '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
Cash & Investments
382.66461.92662.59597.01432.73561.82
Total Debt
7.397.917.065.251.292.73
Net Cash (Debt)
375.26454.01655.53591.76431.44559.09
Net Cash Growth
-33.75%-30.74%10.78%37.16%-22.83%70.63%
Net Cash Per Share
5.046.1210.3811.108.9012.91

Cash Flow & CapEx
Chart
Fiscal YearTTMFY 2024FY 2023FY 2022FY 2021FY 2020
Period EndingMar '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
Operating Cash Flow
-165.43-175.6-222.8-161.56-127.88-32.19
Capital Expenditures
-3.9-4.45-7.39-10.2-2.02-0.64
Free Cash Flow
-169.33-180.05-230.18-171.76-129.89-32.83
Free Cash Flow Growth
------

Margins
Chart
Fiscal YearTTMFY 2024FY 2023FY 2022FY 2021FY 2020
Period EndingMar '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
Gross Margin
93.23%93.45%92.25%--100.00%
Operating Margin
-120.52%-145.17%-6297.28%---132.35%
Pretax Margin
-115.60%-134.73%-5968.50%---130.21%
Profit Margin
-115.60%-134.73%-5968.50%---130.21%
FCF Margin
-77.09%-93.98%-4225.81%---93.81%

Valuation
Chart
Fiscal YearCurrentFY 2024FY 2023FY 2022FY 2021FY 2020
Period EndingAug '26 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
PS Ratio
15.9214.02492.39--99.31